Recent Advances in Nanocarriers for Pancreatic Cancer Therapy

Recent Advances in Nanocarriers for Pancreatic Cancer Therapy provides an overview of emerging modern drug delivery systems focused on nanotechnology for pancreatic cancer therapy, covering molecular pathways, conventional therapy, and novel nanocarriers. It equips scientists, clinicians, and students to make rational treatment approaches based on nanomedicine for improving and extending human life.

Format: Paperback / softback
Length: 494 pages
Publication date: 16 September 2023
Publisher: Elsevier Science Publishing Co Inc

Recent Advances in Nanocarriers for Pancreatic Cancer Therapy is a comprehensive review of emerging strategies in pancreatic cancer therapy, delving into the latest developments in modern drug delivery systems derived from nanotechnology. By providing a holistic understanding of molecular pathways, conventional therapy, and novel nanocarriers mediated drug delivery, this work offers a comprehensive package. The book serves as a valuable resource for disseminating data from various sources, encompassing an overview of molecular pathways, conventional therapy, the application of various nanocarriers, and more. It equips scientists, clinicians, and students with the knowledge to develop rational treatment approaches based on nanomedicine for improving and extending human life against pancreatic cancer.

The utilization of nanocarriers in pancreatic cancer therapy has garnered significant attention in recent years due to their unique properties and potential for targeted drug delivery. Nanocarriers, which are microscopic particles ranging in size from 1 to 1000 nanometers, have the ability to encapsulate drugs and deliver them specifically to cancer cells, minimizing drug exposure to healthy tissues. This targeted approach can enhance the efficacy of chemotherapy and radiation therapy while reducing side effects.

One of the promising strategies in nanocarrier-based pancreatic cancer therapy is the use of liposomes. Liposomes are lipid-based vesicles that can encapsulate both hydrophilic and hydrophobic drugs, allowing for the efficient delivery of a wide range of therapeutic agents. Liposomes have been modified to enhance their stability, biocompatibility, and tumor targeting capabilities, making them ideal candidates for drug delivery to pancreatic cancer cells.

Another promising nanocarrier is polymeric nanoparticles, which are composed of biodegradable polymers such as polylactic acid (PLA) or polyglycolic acid (PGA). Polymeric nanoparticles can be designed to have specific properties, such as size, surface charge, and drug loading capacity, which can be tailored to target specific cancer cells. Polymeric nanoparticles have been shown to improve the delivery of drugs to pancreatic cancer cells, increase their uptake, and enhance their therapeutic efficacy.

In addition to liposomes and polymeric nanoparticles, other nanocarriers such as nanostructured materials, such as gold nanoparticles (AuNPs), have also been explored for pancreatic cancer therapy. AuNPs have unique properties, such as high surface area, photothermal properties, and excellent biocompatibility, which make them ideal for drug delivery and imaging applications. AuNPs have been used in combination with chemotherapy and radiation therapy to enhance their therapeutic effects and improve patient outcomes.

Furthermore, nanocarriers have been used in combination with other therapeutic modalities, such as immunotherapy and gene therapy, to improve the treatment of pancreatic cancer. Immunotherapy involves the use of immune cells to target and destroy cancer cells, while gene therapy involves the introduction of genetic material into cancer cells to modify their behavior. Nanocarriers have been used to enhance the delivery of immunotherapy and gene therapy agents to pancreatic cancer cells, improving their efficacy and reducing side effects.

Despite the promising advancements in nanocarrier-based pancreatic cancer therapy, there are still challenges that need to be addressed. One of the major challenges is the lack of effective drug delivery systems that can specifically target pancreatic cancer cells while minimizing drug exposure to healthy tissues. Another challenge is the development of safe and non-toxic nanocarriers that can be used in combination with other therapeutic modalities without compromising their effectiveness.

In conclusion, recent advances in nanocarriers for pancreatic cancer therapy have shown significant promise in improving patient outcomes and quality of life. Nanocarriers, such as liposomes, polymeric nanoparticles, nanostructured materials, and other emerging technologies, have the potential to enhance the delivery of therapeutic agents to pancreatic cancer cells, increase their uptake, and enhance their therapeutic efficacy. However, further research and development are needed to address the challenges associated with drug delivery and develop safe and effective nanocarrier-based therapies for pancreatic cancer.

Weight: 450g
Dimension: 235 x 191 (mm)
ISBN-13: 9780443191428